Human studies are currently ongoing to assess the promise of oxytocin as a therapeutic agent and to evaluate the potential involvement of disrupted oxytocin actions in the pathophysiology of obesity and metabolic syndrome. This evidence concerns the gene OXT and metabolic syndrome.